Synthesis and Evaluation of a New Generation of Orally Efficacious Benzimidazole-Based Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors as Anticancer Agents
Citations Over TimeTop 12% of 2009 papers
Abstract
Small molecule inhibitors of PARP-1 have been pursued by various organizations as potential therapeutic agents either capable of sensitizing cytotoxic treatments or acting as stand-alone agents to combat cancer. As one of the strategies to expand our portfolio of PARP-1 inhibitors, we pursued unsaturated heterocycles to replace the saturated cyclic amine derivatives appended to the benzimidazole core. Not only did a variety of these new generation compounds maintain high enzymatic potency, many of them also displayed robust cellular activity. For example, the enzymatic IC(50) and cellular EC(50) values were as low as 1 nM or below. Compounds 24 (EC(50) = 3.7 nM) and 44 (EC(50) = 7.8 nM), featuring an oxadiazole and a pyridine moiety, respectively, demonstrated balanced potency and PK profiles. In addition, these two molecules exhibited potent oral in vivo efficacy in potentiating the cytotoxic agent temozolomide in a B16F10 murine melanoma model.
Related Papers
- → NADH can enter into astrocytes and block poly(ADP-ribose) polymerase-1-mediated astrocyte death(2005)39 cited
- → Novel poly(ADP-ribose) polymerase-1 inhibitors(2006)23 cited
- → Novel poly(ADP-ribose) polymerase-1 inhibitors(2011)6 cited
- → Poly(ADP-ribose) Preparation Using Anion-Exchange Column Chromatography(2009)3 cited
- → Amino Acid Specific Modification of Poly(ADP-ribose)polymerase with Monomers and Polymers of ADP-ribose(1992)